Processa Pharmaceuticals, Inc. (PCSA)
NasdaqCM: PCSA
· 即時價格 · USD
2.06
-0.06 (-2.83%)
收盤價： Sep 01, 2026, 3:59 PM
股價、關鍵數字和最新消息，都在這一頁。
Processa Pharmaceuticals, Inc.（PCSA）股價、分析與資料
-3.06% (1D)
| 買價 | 0.05 |
| 市值 | 5.73M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -13.4M |
| 0.96 | |
| 0.65 | |
| 3.15 | |
| -0.55 | |
| P/B (ttm) | 2.16 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 2.62 |
| 成交量 | 9,591 |
| 20 日平均成交量 | 245,949 |
| 開盤價 | 2.08 |
| 前收盤價 | 2.12 |
| 當日區間 | 2.02 - 2.14 |
| 52 週範圍 | 1.67 - 14.25 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 PCSA
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS642...
完整的公司簡介財報驚奇
Processa Pharmaceuticals 已於 Nov 6, 2025 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -1.75 超出預期 0.25, 年增 93.20% 成長.
